
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
Published on November 2, 2021
Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
